2012-09-12 07:46:20 - Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 - a new market research report on companiesandmarkets.com

Angiomax Sales, 2010 - In 2010, Angiomax generated sales of $437m, claiming 1.8% of the total antithrombotic/anticoagulant drug market and a 52% share of direct thrombin inhibitor market.Angiomax Sales Forecast, 2012-2022 - In 2010, Angiomax acquired a market share of more than 50% in the direct thrombin inhibitor market. During the forecast period, the sales of Angiomax will increase moderately until 2016. Patent protection for Angiomax has been extended until 2014. However, The Medicines Company has apparently agreed a deal with Teva Pharmaceuticals, according to which Teva has agreed to not launch any generic versions of Angiomax until 2018. Sales of Angiomax will peak at $555m in 2018 and thereafter decline until 2022. Angiomax will face competition from newer direct

 

 

thrombin inhibitors as well. Overall, sales of Angiomax will grow at a CAGR of 0.9% to 2022.Activase - Activase (alteplase), a recombinant tissue plasminogen activator, was first launched in 1987 by Genentech (US market) and licensee Boehringer Ingelheim (European market under the name Actilyse). It was first marketed in Canada in 1988 and later, in 1991, in Japan through licensees Kyowa Hakko (as Activacin) and Mitsubishi Kasei (as GRPTA).Activase was initially indicated for the treatment of acute myocardial infarction, acute pulmonary embolism and stroke. In 1996, the FDA approved Activase for use in acute ischaemic stroke within the first three hours of symptom onset. Activase was later also approved for this indication in Europe. Usage for this indication has reportedly been low, however.Activase Sales, 2010 - In 2010, the sales of Activase reached $420m, claiming a market share of 1.8%.Activase Sales Forecast, 2012-2022 - Activase will continue to generate increasing revenue as the leading fibrinolytic drug, generating revenue of up to $812m by the year 2019. From 2020 onwards, sales of Activase will begin to decline owing to competition by other drugs in this category. Sales for Activase will grow at a CAGR of 4.5% during the forecast period.Report Scope- Find revenue predictions to 2022 for the overall world market and submarkets
- Discover revenue forecasts to 2022 for 14 drugs, assessing commercial potential
- See revenue forecasts to 2022 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
- Assess leading companies, discovering activities and outlooks
- Review R&D, seeing pipeline trends
- Investigate competition and opportunities influencing sales results
- Find out what will stimulate and restrain the industry and market
- View opinions from our survey of authorities on the sector.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.